Accuray Inc (NASDAQ: ARAY)

Sector: Healthcare Industry: Medical Devices CIK: 0001138723
Market Cap 41,142.92
P/E -1.38
P/S 0.00
Div. Yield 0.00
ROIC (Qtr) -0.25
Total Debt (Qtr) 135.89 Mn
Revenue Growth (1y) (Qtr) -11.99
Add ratio to table...

About

Accuray Incorporated, commonly referred to as Accuray, is a company that operates in the healthcare industry, specifically in radiation therapy. The company is known for developing, manufacturing, and selling innovative solutions for delivering radiation treatments to patients with cancerous or benign tumors. Accuray's main business activities revolve around the development and commercialization of radiation therapy systems. The company boasts two major platforms: the CyberKnife and TomoTherapy. The CyberKnife platform is a robotic radiosurgery...

Read more

Investment thesis

Bull case

  • Accuray’s announced operational overhaul, including a 15 % workforce reduction and centralization of non‑core functions, signals a disciplined approach to margin improvement. The CEO highlights a projected $25 million improvement in annualized operating profitability, with $12 million realized by fiscal year‑end. Even as the company wrestles with tariffs, the systematic cost discipline should offset headwinds, allowing the firm to reallocate capital toward higher‑ROI initiatives. Over the next 12 months the organization is expected to hit a high single‑digit adjusted EBITDA margin run‑rate, a clear catalyst for upside if the transformation sticks.
  • Service revenue rose 4 % YoY and 3 % on a constant currency basis, illustrating a resilient recurring stream that offsets the decline in product sales. The company is expanding its service portfolio into training, data management, and real time monitoring, thereby raising the average price and capturing additional value from the installed base. With a 26.6 % gross margin on services versus 27.7 % the previous year, the firm’s margin‑expansion strategy is already showing early signs of success. As service offerings mature, they are expected to provide a more predictable cash flow and improve overall profitability.
  • Accuray is tightening its distributor relationship model, implementing tiered performance standards and pay for performance incentives. This structure aims to align channel partners more closely with corporate objectives, enhancing sales velocity and market coverage, especially in regions where Accuray lacks a direct sales presence. By formalizing distributor oversight and support, the company can accelerate adoption of its platforms in new geographies, a critical lever in a highly fragmented market. The program also creates a built‑in sales pipeline that could translate into incremental revenue growth over the medium term.
  • Customer feedback consistently highlights a demand for reliability, interoperability, and patient throughput, and the company is aligning its product roadmap to meet those priorities. By focusing engineering resources on high‑ROI projects that incorporate third‑party solutions, Accuray can differentiate its offerings and lock in long‑term commitments. The firm’s emphasis on clinical and economic value will likely drive pricing power, supporting higher margins once the initiatives mature. The disciplined sequencing of roadmap elements should reduce product‑mix volatility and support steady growth.
  • Interviews with hospitals across the United States, China, the European Union, and emerging markets reveal no widespread CapEx contraction; on the contrary, institutions are looking to acquire or lease new equipment. The robotic and helical platform technologies offer high patient throughput, making them attractive even in capital‑constrained environments. Accuray’s ability to offer flexible financing models could further ease adoption and generate incremental sales. This favorable capital environment suggests that the company’s product and service expansion plans are unlikely to be stalled by institutional budget constraints.
Read more

Bear case

  • China remains the company’s most significant growth engine, yet persistent tariffs and a volatile geopolitical climate have eroded both product revenue and margins. The CEO acknowledged that China’s licensing and funding process has become protracted, dampening deal velocity and creating a lag in revenue recognition. Without a clear path to tariff relief, the company’s exposure to this market will continue to weigh on profitability and revenue guidance. The uncertainty makes it difficult to project future growth and increases the risk that the company may miss its adjusted EBITDA targets.
  • Product gross margins fell from 43.5 % to 19.7 % YoY, largely due to China releases and the introduction of new tariffs. Management comments indicated that tariffs added a six‑point drag, while a shift in product mix also contributed another eight points. Such a significant margin compression leaves limited room for further price increases, especially if competitive pressure intensifies. If the company cannot reverse this trend, the margin squeeze could continue, eroding overall profitability.
  • The updated revenue outlook of $440 million to $450 million represents a downgrade from the prior $471 million to $485 million range, reflecting heightened uncertainty in key markets. The guidance cut signals that management does not anticipate the same level of demand that was previously expected, casting doubt on the company’s ability to achieve projected growth. The downgrade also suggests that the company may need to accelerate its transformation initiatives to offset the decline, increasing operational risk. If the guidance continues to slide, the company may face a prolonged period of lower top‑line performance.
  • The company recognized $6.1 million in restructuring charges in the quarter, primarily severance and contract terminations. While the charges were planned, they have reduced cash reserves from $63.9 million to $41.9 million, tightening liquidity. The CFO noted that working capital usage and interest also eroded cash, raising concerns about the company’s ability to finance further investment or weather additional downturns. A limited cash buffer could constrain the firm’s flexibility to pursue strategic acquisitions or R&D investments, potentially hindering long‑term competitiveness.
  • Although service revenue grew modestly, gross margin on services dropped from 27.7 % to 26.6 %, partly due to higher net parts consumption. Service margins are sensitive to the timing of parts usage, and any unforeseen spikes could further erode profitability. Management emphasized that the service expansion initiatives are still in early stages, which may delay the realization of recurring revenue benefits. Until the service portfolio matures, the company’s ability to offset product margin erosion with recurring income remains uncertain.
Read more

Product and Service Breakdown of Revenue (2025)

Fair Value Hierarchy and NAV Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 177.36 Bn 27.31 4.00 12.93 Bn
2 SYK Stryker Corp 124.60 Bn 38.40 4.96 15.86 Bn
3 MDT Medtronic plc 109.93 Bn 23.82 3.10 28.07 Bn
4 BSX Boston Scientific Corp 93.15 Bn 31.94 4.64 11.44 Bn
5 EW Edwards Lifesciences Corp 46.49 Bn 43.68 7.66 0.60 Bn
6 PHG Koninklijke Philips Nv 29.40 Bn 25.00 1.46 9.41 Bn
7 DXCM Dexcom Inc 24.14 Bn 28.78 5.18 -
8 STE STERIS plc 21.56 Bn 30.26 3.70 1.90 Bn